ValiSeek Clinical Development Update

RNS Number : 6667Y

ValiRx PLC

19 May 2016

 

ValiRx Plc

("ValiRx" or "the Company")

ValiSeek Clinical Development Update

London, UK, 19 May 2016: ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to provide a development update on the clinical development of ValiSeek Limited ("ValiSeek), the joint venture between ValiRx and Tangent Reprofiling Limited, which was formed to progress the novel cancer treatment drug, VAL401, towards Clinical Efficacy trials for the treatment of lung cancer and other oncology indications.

Further to our announcement on 16 July 2015 regarding the commencement of the clinical process for the testing of VAL401 in the treatment of patients, ValiSeek is pleased to confirm the initiation of the clinical manufacturing of the Investigation Medicinal Product ("IMP"), VAL401, for its use in the clinical trial: "A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapeutic regimen".

To date, VAL401 oral capsules, in both 1 mg and 5 mg dose strengths, have been manufactured at a qualified European manufacturer; demonstrating suitability for progression towards a licensed product.  The manufacturer is now assembling sufficient quantity of clinical quality VAL401 capsules to commence dosing patients in our Phase 2b trial.

Further stability assays and batch control analysis will be carried out concurrently with the manufacturing process to strengthen the package of information.

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: [phone] www.ValiRx.com
Dr Satu Vainikka, Chief Executive	Tel: [phone]
Tarquin Edwards, Head of Communications.	Tel: [phone] [e-mail]
Mark Treharne, Corporate Development Manager	Tel: [phone] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: [phone]
Liam Murray / Avi Robinson
Northland Capital Partners Limited (Broker)	Tel: [phone]
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking)

About ValiSeek

ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications

About SEEK

Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. SEEK brings safe and low costs medicines to the patients as quickly as possible. It does this by modifying existing medicines to improve their efficacy within current label, dose and regime, by changing the indication but keeping the dose and dosing regime the same or by creating a new medicine when the previous options are unavailable.

Additional information about SEEK is available on the Company's website located at www.seekacure.com

About ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006.

The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials. The product focus is in the targeted analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. It actively manages projects within its portfolio as a trading company.  The ValiRx business model spreads the risks of life science technology development by minimizing financial exposure and running a set of projects to defined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiPharma is the therapeutics division, with two embedded technologies primarily directed at the treatment of cancers.

 2. ValiFinn is the biomarkers and diagnostic development division.  ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology to strengthen the portfolio.

 3. ValiSeek is a joint venture between ValiRx and Tangent Reprofiling Ltd to develop Val401 in lung cancer and potentially other indications.

 

END

 

 

RESBIGDUIXBBGLI